AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch solutions
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch solutions
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02251847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg
Study NCT02251847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cells
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Packed Red Blood Cells
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solutions
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin solutions
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-Lyte
Description: Intravenous fluid used to treat intraoperative hypotension
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroprocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study NCT01367041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vibration
Description: Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
Study NCT02515929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligomeric Proanthocyanidins
Study NCT02515929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06144879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double rods without dual-headed screw
Description: adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)
Study NCT06144879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three rods with one dual-headed screw
Description: adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)
Study NCT06144879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: four rods with two dual-headed screw
Description: adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
Study NCT03159559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-PGE1
Description: Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
Study NCT03395899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1 antibody
Study NCT03395899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: PD-L1 antibody
Study NCT03395899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Highly selective small-molecule inhibitor of MEK1 and MEK2
Study NCT03395899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt
Study NCT03395899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Highly specific humanized monoclonal antibody that targets VEGF
Study NCT03688815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: myocardial perfusion scintigraphy
Description: Myocardial perfusion scintigraphy as it is described in the international literature.
Study NCT02986126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiliency Class
Description: See Arm Description
Study NCT02986126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resource for Services (RS)
Description: See Resource for Services (RS) Description
Study NCT02528825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil titration
Description: Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
Study NCT02096016 — intervention group
Intervention type: PROCEDURE
Intervention: Human Papilloma Virus test from the vaginal vault
Description: Surveillance after surgical treatment of early stage cervical cancer
Study NCT01685775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal/transumbilical
Study NCT01685775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needlescopic with 3 trocars
Study NCT06375070 — intervention group
Intervention type: PROCEDURE
Intervention: PFO closure
Description: PFO closure
Study NCT06375070 — intervention group
Intervention type: DRUG
Intervention: anticoagulant
Description: rivaroxaban
Study NCT00706446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
Study NCT00706446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
Study NCT00706446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
Study NCT00706446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
Study NCT00706446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
Study NCT00706446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
Study NCT00706446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
Study NCT02956343 — intervention group
Intervention type: DEVICE
Intervention: Five minutes pulse wave recording
Description: Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
Study NCT00933153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus
Description: Ensure plus supplement with meals
Study NCT00933153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meals on Wheels
Description: Two Meals on Wheels twice daily
Study NCT00933153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meals on Wheels
Description: Two Meals on Wheels twice daily
Study NCT02839317 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological
Description: comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
Study NCT03733236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ISS Active Stimulation
Description: ISS SPG stimulation and standard of care
Study NCT04341090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
Study NCT02654301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test 1
Description: sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
Study NCT02654301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test 2
Description: sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
Study NCT02654301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test 3
Description: sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
Study NCT02654301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: sucrose 50 g + deionized water 100 g
Study NCT04337788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth applications
Description: telehealth applications during 30 days/patient
Study NCT01937299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
Study NCT01879059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: short period of inactivity (5 days) followed by a return to physical activity (1 day)
Study NCT00481624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa plus Iron
Description: 1. One (1) injection of Procrit®, by needle, inserted just under the skin;~2. 125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan.
Study NCT03114787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study on patients with respiratory resuscitation
Description: Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
Study NCT01937299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT01937299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% ophthalmic solution
Study NCT01937299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost 0.004% ophthalmic solution
Study NCT00091858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: 6.75 mcg/kg Q4W
Study NCT00091858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q4W
Study NCT03640819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tattooing of biopsied node
Description: Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
Study NCT03167918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: gave each patient 0.5 g bid，
Study NCT03167918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefuzhuyu Decoction
Description: gave each patient100 ml bid，po
Study NCT03167918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefuzhuyu Decoction & Calcium dobesilate
Description: gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
Study NCT03167918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: gave each patient 1000 mg, bid, PO
Study NCT03167918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: gave each patient 0.5 mg bid, PO
Study NCT06370793 — intervention group
Intervention type: OTHER
Intervention: Patient with schizophrenia without intervention
Description: Patients with schizophrenia identified based on exposures of interest to the study
Study NCT04343144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
Study NCT03962829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mCPP
Description: Healthy participants administrate one capsule of mCPP (30mg)
Study NCT03962829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Healthy participants administrate one capsule of placebo (containing lactose)
Study NCT00655889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (azficel-T)
Description: 1. Collection of biopsy from palate~2. Papillary priming procedure~3. Seven injection treatments to target sites~4. Performance of study assessments (investigator and subject)
Study NCT03479905 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Salter nasal cannula
Description: Oxygen will be delivered via standard nasal cannula during colonoscopy
Study NCT03479905 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Face mask
Description: Oxygen will be delivered via face mask during colonoscopy
Study NCT03479905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
Study NCT02255747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Study NCT03183817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care at distance
Description: Person-centred care at distance through an eHealth platform
Study NCT03087240 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental Prophylaxis
Description: Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
Study NCT01888900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUAL
Description: Asunaprevir and Daclatsvir
Study NCT01888900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUAD
Description: Asunaprevir, daclatsvir, peginterferon and ribavirin
Study NCT03087240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Prophylaxis
Description: Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
Study NCT01281696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, etoposide, cisplatin
Description: Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
Study NCT01281696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Description: Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis